Index

Show indicators by:

  • Cancer Control Domain
  • Disease Site
  • Dashboard
  • Disease Site
    • Breast
      • Breast cancer screening
      • Screening in underserved populations
      • Breast cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Breast cancer resections that are mastectomies
        • The use of breast-conserving surgery versus mastectomies for breast cancer resections
      • Radiation therapy
        • Post-operative radiation therapy for stage I or II breast cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Breast cancer screening outside recommended guidelines
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Colorectal
      • Colorectal cancer screening
      • Geographic variation in colorectal cancer risk
      • Screening in underserved populations
      • Colorectal cancer diagnosis wait time
      • Capture of stage
      • Stage distribution
      • Surgery
        • Removal and examination of 12 or more lymph nodes in colon resections
        • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
      • Radiation therapy
        • Pre-operative radiation therapy for patients with stage II or III rectal cancer
      • Post-operative chemotherapy for stage III colon cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Lung
      • Capture of stage
      • Stage distribution
      • Geographic variation in lung cancer risk
      • Resection rates for stage II or IIIA Non-snmall cell lung cancer patients
      • Post-operative chemotherapy for stage II or IIIA non-small cell lung cancer patients
      • Place of death
      • Adult clinical trial participation
      • Cancer research investment
      • Incidence and mortality rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Prostate
      • PSA testing
      • Prostate risk profile
      • Capture of stage
      • Stage distribution
      • Prostate wait times for surgery
      • Prostate wait times for radiation therapy
      • Radical prostatectomy: open versus laparoscopic surgery
      • Prostate patterns of care: radiation and surgical treatment
      • Prostate access to palliative radiation
      • Prostate clinical trials participation
      • Adult clinical trial participation
      • Prostate cancer research investment
      • Cancer research investment
      • Incidence & Mortality Rates
      • Five-year net survival by income quintile for several cancers in Canada
    • Cervical
      • Human papillomavirus (HPV) vaccination
      • Cervical cancer screening
      • Screening in underserved populations
    • Pancreas
      • Incidence and mortality rates
    • Stage Distribution
  • Province & Territory
  • 1. Prevention
  • 2. Screening
  • 3. Diagnosis
  • 4. Treatment
  • 5. Person-Centred Perspective
  • 6. Research
  • 7. Appropriateness
  • 8. Long-term outcomes
  • Smoking prevalence
  • Smoking behaviours in current cancer patients
  • Smoking cessation
  • Second-hand smoke exposure
  • Geographic variation in lung cancer risk
  • Alcohol consumption
  • Adult overweight and obesity
  • Active transportation
  • Physical inactivity
  • Human papillomavirus (HPV) vaccination
  • Fruit and vegetable consumption
  • Geographic variation in colorectal cancer risk
  • Cervical cancer screening
  • Breast cancer screening
  • Colorectal cancer screening
  • PSA testing
  • Screening in underserved populations
  • Breast cancer diagnosis wait times
  • Colorectal cancer diagnosis wait times
  • Capture of stage
  • Stage distribution
  • Prostate risk profile
  • Surgery
  • Radiation therapy
  • Systemic therapy
  • Removal and examination of 12 or more lymph nodes in colon resections
  • Resection rates for stage II or III rectal cancer, stage III colon cancer and stage II or IIIA non-small cell lung cancer patients
  • The use of breast-conserving surgery versus mastectomies for breast cancer resections
  • Breast cancer resections that are mastectomies
  • High-risk, resource-intensive surgeries for esophageal, pancreatic, liver, lung and ovarian cancers in Canada
  • Prostate wait times for surgery
  • Radical prostatectomy: open versus laparoscopic surgery
  • Radiation therapy wait times
  • Radiation therapy utilization and capacity
  • Pre-operative radiation therapy for patients with stage II or III rectal cancer
  • Post-operative radiation therapy for patients with stage I or II breast cancer
  • Prostate wait times for radiation therapy
  • Prostate patterns of care: radiation and surgical treatment
  • Post-operative chemotherapy for stage III colon cancer patients
  • Post-operative chemotherapy for patients with stage II or IIIA non-small cell lung cancer
  • Screening for distress
  • Patient satisfaction
  • Place of death
  • Prostate access to palliative radiation
  • Adult clinical trial participation
  • Prostate clinical trials participation
  • Pediatric clinical trial participation
  • Cancer research investment
  • Prostate cancer research investment
  • Breast cancer screening outside of guidelines
  • Breast cancer mastectomies done as day surgery
  • Intensive care use in the last two weeks of life
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Pancreatic cancer
  • Five-year net survival by income quintile for several cancers in Canada
System Performance Logo
System Performance
  • About
  • Reports
  • Français
  • Home
  • Cancer control domain
  • 4. Treatment
  • Radiation therapy
  • Prostate wait times for radiation therapy

Prostate wait times for radiation therapy

  • Charts and Tables

    Charts and Tables

    Figure 4.19

    90th percentile radiation therapy wait times from ready-to-treat to start of radiation for prostate cancer, by province — 2013 treatment year

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    "-" Data not available.
    Wait time is from ready-to-treat to start of radiation.
    The Canadian Association of Radiation Oncology (CARO) has set a target of 14 days (10 working days) from consultation to first radiation therapy fraction.
    The national target is for 90% of patients to receive radiation therapy within 28 days from ready-to-treat to start of treatment.
    Data source: Provincial cancer agencies.

    Data Table

    Province90th Percentile Wait Time (days)Percentage within national target (%)
    BC4082.4
    AB3286.9
    SK2790.8
    MB2799.4
    ON1895.1
    QC--
    NB2989.3
    NS3186.9
    PE--
    NL3088.6

    + Expand Table

    "-" Data not available.
    Wait time is from ready-to-treat to start of radiation.
    The Canadian Association of Radiation Oncology (CARO) has set a target of 14 days (10 working days) from consultation to first radiation therapy fraction.
    The national target is for 90% of patients to receive radiation therapy within 28 days from ready-to-treat to start of treatment.
    Data source: Provincial cancer agencies.

    Figure 4.20

    Median and 90th percentile radiation therapy wait times from ready-to-treat to start of radiation for prostate cancer, by province, by risk category — 2013 treatment year

    • Download & Export

      Figure

      •  

      Data Table

      • CSV
      • Excel
      • Json
      • XML

    "-" Data not available.
    AB: Risk group cannot be assigned for more than 55% of patients.
    NS: Data were not available due to incomplete disease information for 2013 cases.
    The Canadian Association of Radiation Oncology (CARO) has set a target of 14 days (10 working days) from consultation to first radiation therapy fraction.
    The national target is for 90% of patients to receive radiation therapy within 28 days from ready-to-treat to start of treatment.
    Data source: Provincial cancer agencies.

    Data Table

    ProvinceMedian wait time (days)90th Percentile wait time (days)
    BC High-risk1228
    BC Intermediate-risk2262
    BC Low-risk2879
    AB High-risk--
    AB Intermediate-risk--
    AB Low-risk--
    SK High-risk621
    SK Intermediate-risk319
    SK Low-risk731
    MB High-risk2328
    MB Intermediate-risk2328
    MB Low-risk2123
    NB High-risk831
    NB Intermediate-risk1021
    NB Low-risk1636
    NS High-risk--
    NS Intermediate-risk--
    NS Low-risk--
    PE High-risk2139
    PE Intermediate-risk1927
    PE Low-risk2125
    NL High-risk--
    NL Intermediate-risk--
    NL Low-risk--

    + Expand Table

    "-" Data not available.
    AB: Risk group cannot be assigned for more than 55% of patients.
    NS: Data were not available due to incomplete disease information for 2013 cases.
    The Canadian Association of Radiation Oncology (CARO) has set a target of 14 days (10 working days) from consultation to first radiation therapy fraction.
    The national target is for 90% of patients to receive radiation therapy within 28 days from ready-to-treat to start of treatment.
    Data source: Provincial cancer agencies.

  • Data specifications

    Data specifications

    Data and measurement considerations

    • The criteria for assigning risk based on the GUROC Canadian Consensus definition include non-metastatic patients only. This means that metastatic patients were excluded from the analysis showing wait times by risk category (Figure 4.20). For other analyses of radiation therapy wait times, all prostate cancer patients (non-metastatic and metastatic) were included (Figure 4.19).
    • The indicator examining the median and 90th percentile wait times by risk category includes data on patients who received treatment to the primary cancer site only (the prostate gland) (Figure 4.20). Indicator data on the 90th percentile wait times (not by risk category) are consistent with provincial wait times definition, which means that waits could be reported by primary site (prostate gland) or by the site receiving treatment (i.e., metastatic site) (Figure 4.19).
    • “Ready-to-treat” is the starting point for the wait time measurement. While considerable effort has gone into developing and adopting a standardized definition for this term, interprovincial variations may persist.
    • Radiation therapy wait times include wait times for external beam radiation therapy (EBRT) or brachytherapy where available.
    • The Canadian Association of Radiation Oncology (CARO) has set a target of 10 working days (14 calendar days) from the day of consultation or requisition to the start of radiation therapy for all cancer patients.554 This target is shown in the figures along with the national target of 28 days.

    Wait times for radiation therapy

    • Definition:
      1. Median and 90th percentile radiation therapy wait time from ready-to-treat to start of radiation therapy, measured in days
      2. The percentage of cases treated with radiation therapy within 4 weeks from ready-to-treat

      The population includes prostate cancer cases (men aged 35 and older) receiving radiation therapy in 2013 that have wait time data collected.

    • Measures:
      1. Wait time
        1. Median wait time (days)
        2. 90th percentile wait time (days)
      2. Percentage of patients starting treatment within target timeframe (4 weeks after being deemed ‘ready-to-treat’)
    • Numerator: Of the denominator, the total number of prostate cancer cases (men aged = 35) starting radiation therapy within 4 weeks of being ‘ready-to-treat’
    • Denominator: Total number of prostate cancer cases receiving radiation therapy within 2013
    • Data source: Provincial cancer agencies
    • Measurement timeframe: 2013 treatment year
    • Stratification variables: Province, risk category* (low, intermediate, high)
      *Refer to ‘Age-standardized incidence rates by risk category’ under ‘2. Diagnosis’ section for detail.
    • Provinces submitting data: BC, AB, SK, MB, ON, NB, NS, PE, NL
    • Province specific notes: AB: For 2013, data included all cases who had radiation therapy at a Cancer Control Alberta Facility with their first treatment between Jan 1, 2013 – Dec 31, 2013; it includes those who were living in another province at time of diagnosis but receiving radiation therapy in Alberta. Tumor group classification for this indicator is based on referral tumor groups. Data by risk category were not available since risk category could not be assigned for more than 55% of patients. SK: For 2013, data were reported by treatment site, any RT treatment modality was included. NS: For 2013, wait time were computed using the same rules for producing wait time for NS Department of Health and Wellness. As such, wait time were based on patient first courses of treatment in the period of interest. Data by risk category were not available due to incomplete disease information for 2013 cases. PE: For 2013, data were based on new treatment starts within the timeframe of 2013. Individual cancer patients could have more than one treatment start in the timeframe and could therefore be counted more than once.
    • General notes:
      1. All behaviour codes are included.
      2. Radiation therapy to the primary site only.
      3. Disease Site and Morphology Codes: In order to identify prostate cancer, the provinces used whatever disease site and morphology codes they typically use within their provincial registry for reporting incident cases by disease site.
      4. There are known discrepancies in the ways in which different provinces measure wait times. One of the key sources of variation is how “ready-to-treat” is defined. Efforts are underway to standardize these definitions. The following section outlines the definitions used by the different provinces, collected in 2013:
        • Provincial definitions:
          AB: The date when the patient is physically ready to commence treatment. BC: The date at which both oncologist and patient agree that treatment can commence. Being ready to treat requires that all diagnostic tests and procedures required to assess the appropriateness of, indications for, and fitness to undergo radiation therapy are complete. MB: The date when a decision has been made by the radiation oncologist and is agreed to by the patient that radiation therapy is appropriate and should commence AND the patient is medically ready to start treatment AND the patient is willing to start treatment. NB: The date when any planned delay is over and the patient is ready to begin treatment from both a social/personal and medical perspective. NL: The date when all pre-treatment investigations and any planned delay are over, and the patient is ready to begin the treatment process from both a social/ personal and medical perspective. NS: The date when all pre-treatment investigations and any planned delay are over, and the patient is ready to begin the treatment process from both asocial/personal and medical perspective. Nova Scotia did not have a ready to treat date until February 2010; a proxy date was used prior to this time. ON: The time from when the specialist is confident that the patient is ready to begin treatment to the time the patient receives treatment. PE: The date when all pre-treatment investigations and any planned delay are over, and the patient is ready to begin the treatment process from both a social/personal and medical perspective. QC: At consultation, the radiation oncologist enters the date at which the patient will be ready to treat on a formulary requesting treatment. SK: The date when the patient is ready to receive treatment, taking into account clinical factors and patient preference. In the case of radiation therapy, any preparatory activities (e.g., simulation, treatment planning, dental work) do not delay the ready to treat date.
  • Related indicators

    Related Indicators

    Prostate patterns of care: radiation and surgical treatment

    Percentage of low-risk prostate cancer patients (men aged ≥ 35) receiving various types of radiation therapy ,† by province — 2010 diagnosis year
    View this indicator
    Prostate wait times for surgery

    Median and 90th percentile surgery wait times from booking date to surgery for prostate cancer, by province — 2014
    View this indicator
  • About Us
  • Careers
  • Contact
  • Media centre
  • Share your feedback
  • About our new site

  • Français Language toggle.

Other related sites:

  • Canadian Partnership for Tomorrow’s Health
  • Canadian Cancer Research Alliance
  • Canadian Cancer Trials
  • facebook
  • twitter
  • youtube
  • linkedin
    CPAC Logo

    Questions about cancer?

    For information about cancer treatment and support for patients, please contact the Canadian Cancer Society at 1-888-939-3333 or by completing this online form.

  • AODA compliance
  • Privacy policy
  • Terms of use
  • FAQ
  • Site map
  • About this site
© Canadian Partnership Against Cancer Corporation